oaioai:CiteSeerX.psu:10.1.1.613.835

Original Article In vitro treatment of dendritic cells with tacrolimus: impaired T-cell activation and IP-10 expression

Abstract

Background. High doses (10–6–10–8M) of tacrolimus (FK506) were reported to induce a type-2 T-helper cell (Th2)-promoting function in developing dendritic cells (DC). We used a therapeutic dose (2.4 10–9M) of tacrolimus to investigate its effect on human monocyte-derived DC. Methods. Using untreated and treated immature and mature DC we compared T cell-activating capacity, surface marker expression, T cell and DC cytokine pro-file and transcription of genes coding for a panel of DC function-related molecules. Results. Tacrolimus-treated mature DC had reduced T-cell stimulatory capacity. Although interleukin (IL)-12 production of DC was impaired, they did not promote Th2 development as T cells activated by tacrolimus-treated DC produced less interferon (IFN)-, IL-4 and IL-10. The up-regulation of the T-cell activation marker CD69 and the production of IL-2 were impaired. In addition, tacrolimus-treated DC produced less IP-10 (CXCL10), which is known to be involved in allograft rejection. Other molecules related to DC function remained unchanged. Conclusions. Tacrolimus treatment reduces the ability of DC to stimulate T cells and the impaired production of DC-derived IP-10 (CXCL10) and IL-12 might play a role in the immunosuppressive action of tacrolimus

Similar works

Full text

thumbnail-image
oaioai:CiteSeerX.psu:10.1.1.613.835Last time updated on 10/29/2017

This paper was published in CiteSeerX.

Having an issue?

Is data on this page outdated, violates copyrights or anything else? Report the problem now and we will take corresponding actions after reviewing your request.